A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: A pilot study

Mediterranean Journal of Nutrition and Metabolism

Volumn 1, Issue 1, 2008, Pages 33-36

  Cicero, Arrigo F G ^a   Derosa, Giuseppe ^b   Bove, Marilisa ^a   Grandi, Elisa ^a   Uliassi, Elisa ^a   Borghi, Claudio ^a   Gaddi, Antonio V ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Berberine; Hypercholesterolemia; Nutraceuticals; Phytosterols; Statin intolerance

Indexed keywords

EID: 81255160815     PISSN: 1973798X     EISSN: 19737998     Source Type: Journal    
DOI: 10.3233/s12349-008-0005-4     Document Type: Article

References (24)

1. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK (2006) Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 166(21): 2307-2313
2. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute (2006). AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation, 113: 2363-2372.
3. Poluzzi E, Strahinja P, Vaccheri A, Vargiu A, Silvani MC, Motola D, Marchesini G, De Ponti F, Montanaro N (2007) Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. Br J Clin Pharmacol 63(3): 346-355
4. McKenney JM (2006) An assessment of statin safety. Am J Manag Care 12[Suppl 11]:S310-S317
5. Anfossi G, Massucco P, Bonomo K, Trovati M (2004) Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 14(4): 215-224
6. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, Sripathi N, Wortmann RL, Phillips PS (2006) Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 34(2): 153-162
7. Daskalopoulou SS, Mikhailidis DP (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 22(3): 511-528
8. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357(22): 2248-2261
9. Editors (2008) In brief: Zetia and Vytorin: the ENHANCE study. Med Lett Drugs Ther 50(1278): 5
10. Wanner C, Krane V (2006) Lessons learnt from the 4D trial. Nephrol Ther 2(1): 3-7
11. Cicero AFG, Derosa G, Gaddi A (2004) What herbalists suggest to our diabetic patients in order to improve their glycaemic control? Evaluation of scientific evidences and potential risks. Acta Diabetol 41(3): 91-98
12. Cicero AFG, Gaddi AV, Borghi C (2005) Complementary medicine for hypertension: what evidence for herbalists suggestion? Evaluation of risks and potential applications. Evid Based Integrative Med 2(1): 47-55
13. Cicero AFG, Linarello S, Nascetti S, Gaddi A (2002) Scientific level evidence of suggestions given by 685 Italian herbalists for the dyslipidemias treatment. Book of abstracts. XVI Congresso Nazionale SISA. Nutr Metab Cardiovasc Dis 12(4): 237
14. Warnick GR, Benderson J, Albers JJ (1982). Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem, 28: 1379-1388.
15. European Diabetes Policy Group (1999). A desktop guide to type 2 diabetes mellitus. Diab Med, 16: 716-730.
16. Norman GR, Streiner DL (2000) Biostatistics: the bare essentials, 2nd edn. Decker, Hamilton, pp 139-144
17. Caron MF, White CM (2001) Evaluation of the antihyperlipidemic properties of dietary supplements. Pharmacotherapy 21(4): 481-487
18. Cicero AFG, Brancaleoni M, Laghi L, Donati F, Mino M (2005). Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complem Ther Med, 13: 273-278.
19. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10(12): 1344-1351
20. Cicero AFG, Rovati L, Setnikar I (2007) Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents in humans. Arzneimittelforschung 57(1): 26-30
21. Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G (2005) Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 25(2): 171-183
22. Prasad GV, Wong T, Meliton G, Bhaloo S (2002) Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 74(8): 1200-1201
23. Packard CJ (2004) Evolution of the HMG CoA reductase inhibitors (statins) in cardiovascular medicine. Br J Cardiol 11(2): 129-136
24. Cholesterol Treatment Trialists’ (CTT) Collaborators (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet, 366: 1267-1278.